A new age of personalised treatment for prostate cancer

https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/eb/40/eb/eb40ebd8-a2e7-1cbe-578b-ea6d7a5769c2/mza_3992128735508575063.jpg/600x600bb.jpg

CORDIScovery – unearthing the hottest topics in EU science, research and innovation

CORDIScovery

50 episodes

4 days ago

CORDIScovery is a monthly podcast featuring a panel discussion between guests at the forefront of their scientific fields. From threats to biodiversity to the future of space exploration, if you want to hear how the EU’s cutting-edge research is taking on the key issues challenging us today, then be sure to download and listen to what Europe’s leading scientists have to say. CORDIScovery is produced by CORDIS, whose mission is to share the results of the very best of EU-funded research.

Science

RSS

All content for CORDIScovery – unearthing the hottest topics in EU science, research and innovation is the property of CORDIScovery and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Science

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_episode/11917090/11917090-1720513638572-dc2c00dd70c5b.jpg

A new age of personalised treatment for prostate cancer

CORDIScovery – unearthing the hottest topics in EU science, research and innovation

30 minutes 5 seconds

1 year ago

A new age of personalised treatment for prostate cancer

Computational power, AI, genomics: the treatment and diagnosis of prostate cancer is advancing rapidly. This episode finds out how.

A leap forward in the diagnosis and treatment would be very welcome: prostate cancer is the second most frequent malignancy in men. In 2020 alone, around one and a half million new cases and almost half a million deaths were registered worldwide. To explore new diagnostics and treatment are:

Jan Tkac, founder and chief scientific officer at Glycanostics, in Slovakia. The company has developed an innovative diagnostic test for cancer, based on novel biomarkers. Jan is also keen to explore how different sports relate to the levels of endorphin release.

Harald Mischak, chief scientific officer of Mosaiques Diagnostics & Therapeutics, Germany. Harald is focused on understanding the underlying molecular structures of certain types of cancers.

Joaquin Mateo, group leader of the Prostate Cancer Translational Research Group at Vall d’Hebron Institute of Oncology, in Barcelona. He is especially interested in the development of novel forms of precision medicine.

For more info on the projects featured, visit: https://europa.eu/!dgTGkb